 NRX Pharmaceuticals Inc NASDAQ: NRXP is trading significantly higher Thursday after the company announced the Journal of Infectious Diseases and Treatment published trial data of aviptadil in high comorbidity patients suffering from critical COVID-19 with respiratory failure. The study reported 60-day survival in 81 of those treated with aviptadil, compared to 21 survival among those who received standard of care treatment at the Houston Methodist Hospital. 